Table 2.
The top list of drug candidates identified by our connectivity map analysis using the gene expression profiles of the peripheral blood mononuclear cell (PBMC) samples of three SARS-CoV-2 infected patients, the bronchoalveolar lavage fluid (BALF) samples of two SARS-CoV-2 infected patients6 and the PBMC samples of ten SARS-CoV infected patients7
| Connectivity Map Score | Compound BRD ID | Name | Description |
|---|---|---|---|
| ARS-CoV-2 (PBMC) | |||
| −99.02 | BRD-K07762753 | Aminopurvalanol-a | Tyrosine kinase inhibitor |
| −98.59 | BRD-K50836978 | Purvalanol-a | CDK inhibitor |
| −98.39 | BRD-K02113016 | Olaparib | PARP inhibitor |
| −96.77 | BRD-K69932463 | AZD-8055 | MTOR inhibitor |
| −96.35 | BRD-K67566344 | KU-0063794 | MTOR inhibitor |
| −95.86 | BRD-K98490050 | Amsacrine | Topoisomerase inhibitor |
| −95.74 | BRD-K04546108 | JAK3-inhibitor-VI | JAK inhibitor |
| −95.56 | BRD-K56334280 | Amonafide | Topoisomerase inhibitor |
| −95.53 | BRD-A82371568 | Clofarabine | Ribonucleoside reductase inhibitor |
| −95.42 | BRD-K12184916 | Dactolisib | MTOR inhibitor |
| SARS-CoV-2 (BALF) | |||
|---|---|---|---|
| −98.38 | BRD-K39569857 | Avrainvillamide-analog-3 | nucleophosmin inhibitor |
| −97.78 | BRD-K00615600 | AG-14361 | PARP inhibitor |
| −97.67 | BRD-K50387473 | XMD-892 | MAP kinase inhibitor |
| −96.65 | BRD-U51951544 | ZG-10 | JNK inhibitor |
| −94.99 | BRD-K00317371 | RITA | MDM inhibitor |
| −94.48 | BRD-K68191783 | ALW-II-38-3 | Ephrin inhibitor |
| −94.29 | BRD-A39646320 | HC-toxin | HDAC inhibitor |
| −93.98 | BRD-K54256913 | MK-1775 | WEE1 kinase inhibitor |
| −92.84 | BRD-K87932577 | CDK1-5-inhibitor | CDK inhibitor |
| −90.73 | BRD-A29901043 | KIN001-127 | ITK inhibitor |
| SARS-CoV (PBMC) | |||
|---|---|---|---|
| −98.94 | BRD-K87142802 | Veliparib | PARP inhibitor |
| −95.37 | BRD-A35338386 | NECA | Adenosine receptor agonist |
| −95.26 | BRD-K11853856 | PJ-34 | PARP inhibitor |
| −92.96 | BRD-A53952395 | Prilocaine | Local anesthetic |
| −91.80 | BRD-K32977963 | Eugenol | Androgen receptor antagonist |
| −91.56 | BRD-A09495397 | Bicuculline | GABA receptor antagonist |
| −91.32 | BRD-K82164249 | Andarine | Androgen receptor modulator |
The default connectivity map score5 of −90.0 was used as the cutoff threshold to determine the top list, i.e., only those drug candidates with the connectivity scores of the query ranked to the top 10% of the reference perturbations were selected. PARP1 inhibitors (i.e., olaparib, veliparib, and PJ-34) were chosen into the top list (shown in bold). For the connectivity map analysis on the gene expression data of SARS-CoV-2 infected patients, only top 10 drug candidates are listed below, and the remaining drug candidates are shown in Supplementary Table S2